Ireland TYSABRI (Natalizumab) Observational Program (iTOP)
Phase of Trial: Phase III
Latest Information Update: 10 May 2018
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Registrational
- Acronyms iTOP
- Sponsors Biogen
- 03 May 2018 Status changed from active, no longer recruiting to completed.
- 10 Jul 2015 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 10 Jul 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov record.